Insulet Stock Quote Today

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:3em;padding-top: 38px;;'>POD</div>
Insulet is trading at 211.29 as of the 10th of July 2020, which is 1.73 percent increase since the beginning of the trading day. The stock's lowest day price was 203.46. Insulet has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 30 days. Equity ratings for Insulet are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 11th of April 2020 and ending today, the 10th of July 2020. Click here to learn more.
Analyze Filter   Report: 6th of August 2020

6 100 

Insulet Profile

The upcoming quarterly report is expected on the 6th of August 2020. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. Insulet operates under Medical Devices classification in the United States and is traded on BATS Exchange. It employs 1350 people. more on Insulet
Legal NameInsulet
CEO and President and DirectorPatrick SullivanView All
Thematic Classifications
Active investing themes Insulet currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Insulet. The Insulet consensus assessment is calculated by taking the average estimates from all of the analysts covering Insulet
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Insulet financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 6 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares54.4 M60.6 M
Moderately Down
Slightly volatile
Weighted Average Shares Diluted55.5 M62.3 M
Fairly Down
Slightly volatile
Net Cash Flow from Operations106.2 M98.4 M
Significantly Up
Slightly volatile
Total Assets1.2 B1.1 B
Significantly Up
Slightly volatile
Total Liabilities1.2 B1.1 B
Significantly Up
Slightly volatile
Current Assets637.7 M591 M
Significantly Up
Slightly volatile
Current Liabilities170.2 M157.7 M
Significantly Up
Slightly volatile
Total Debt172.3 M159.7 M
Significantly Up
Slightly volatile
Return on Average Assets1.211.1199
Significantly Up
Slightly volatile
Gross Margin56.265.0637
Fairly Down
Slightly volatile
Asset Turnover0.880.7127
Fairly Up
Very volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Insulet available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong HoldOvervalued
Financial Strength
Insulet financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Insulet success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
Insulet (PODD) is traded on BATS Exchange in USA and employs 1,350 people. The company currently falls under 'Large-Cap' category with current market capitalization of 13.83 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Insulet's market, we take the total number of its shares issued and multiply it by Insulet's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Insulet conducts business under Healthcare sector and is part of Medical Devices industry. The entity has 65.45 M outstanding shares of which 3.08 M shares are at this time shorted by private and institutional investors with about 5.7 trading days to cover. INSULET CORPORATI currently holds about 321.6 M in cash with 88.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.1.
Check Insulet Probability Of Bankruptcy

Ownership Allocation (%)

Insulet Stock Price Odds Analysis

Odds Down 211.29HorizonTargetOdds Up 211.29
93.53%30 days
Based on a normal probability distribution, the odds of Insulet to move above the current price in 30 days from now is about 6.41 (This Insulet probability density function shows the probability of Insulet Stock to fall within a particular range of prices over 30 days) .

Insulet Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Nelson Van Denburg Campbell Wealth Management Group LlcCommon Shares3.6 K702 K
Fmr LlcCommon Shares9.4 M1.6 B
Citadel Advisors LlcDebt153.5 M281.4 M
View Insulet Diagnostics

Insulet Income Statement Over Time

Insulet Income Statement is one of the three primary financial statements used for reporting Insulet's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Insulet revenue and expense. Insulet Income Statement primarily focuses on the company's revenues and expenses during a particular period. Insulet Cost of Revenue is expected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 158.46 Million. The current year Gross Profit is expected to grow to about 143.9 M, whereas Earning Before Interest and Taxes EBIT is expected to decline to (59 M). View More Fundamentals

Insulet Stock Against Markets

Did you try this?

Run Balance Of Power Now


Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Insulet Upcoming and Recent Events

Insulet Company Earnings Announcements Dates

Upcoming Quarterly Report6th of August 2020
Next Earnings Report3rd of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End23rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Insulet Corporate Directors

Sally Crawford Lead Independent Director
John Fallon Independent Director
Daniel Levangie Independent Director
Please check Your Equity Center. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page